KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elevance Health (ELV) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Elevance Health (ELV) over the last 17 years, with Q4 2025 value amounting to $9.5 billion.

  • Elevance Health's Cash & Equivalents rose 1451.5% to $9.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $9.5 billion, marking a year-over-year increase of 1451.5%. This contributed to the annual value of $9.5 billion for FY2025, which is 1451.5% up from last year.
  • Latest data reveals that Elevance Health reported Cash & Equivalents of $9.5 billion as of Q4 2025, which was up 1451.5% from $8.7 billion recorded in Q3 2025.
  • Elevance Health's 5-year Cash & Equivalents high stood at $10.9 billion for Q3 2023, and its period low was $4.9 billion during Q4 2021.
  • Over the past 5 years, Elevance Health's median Cash & Equivalents value was $7.7 billion (recorded in 2024), while the average stood at $7.7 billion.
  • Per our database at Business Quant, Elevance Health's Cash & Equivalents skyrocketed by 7448.08% in 2021 and then tumbled by 3861.17% in 2024.
  • Quarter analysis of 5 years shows Elevance Health's Cash & Equivalents stood at $4.9 billion in 2021, then surged by 51.37% to $7.4 billion in 2022, then decreased by 11.66% to $6.5 billion in 2023, then increased by 27.0% to $8.3 billion in 2024, then increased by 14.51% to $9.5 billion in 2025.
  • Its Cash & Equivalents was $9.5 billion in Q4 2025, compared to $8.7 billion in Q3 2025 and $8.6 billion in Q2 2025.